{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:55Z","timestamp":1789707835819,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Lynch syndrome (LS) is a hereditary cancer predisposition syndrome associated with multiple malignancies, including colorectal cancer and upper tract urothelial carcinoma (UTUC). We report a 61-year-old woman who initially presented with ascending colon adenocarcinoma and underwent laparoscopic right hemicolectomy. Immunohistochemistry showed loss of MLH1 and PMS2 expression, suggesting deficient mismatch repair. Ten months later, she developed a right renal pelvic mass, which was confirmed by ureteroscopic biopsy as invasive high-grade urothelial carcinoma with squamous differentiation rather than metastatic colon cancer. The urothelial tumor also showed an abnormal MLH1\/PMS2 immunophenotype. Subsequent molecular evaluation included plasma cell-free DNA profiling for somatic genomic characterization and peripheral-blood germline analysis for hereditary cancer assessment. Germline testing identified a heterozygous pathogenic variant in NM_000249.4(\n                    <jats:italic>MLH1<\/jats:italic>\n                    ):c.503dup (p.Asn168fs), establishing the diagnosis of Lynch syndrome. Because the patient strongly wished to preserve renal function, she received single-agent toripalimab at 240 mg every 3 weeks instead of radical nephroureterectomy. Contrast-enhanced CT after three cycles showed tumor reduction, and after six cycles demonstrated further marked regression of the right renal pelvic and upper ureteral lesion, with only residual focal thickening of the renal pelvic wall. At the last follow-up in April 2026, the patient remained clinically stable without evidence of colorectal cancer recurrence or progression of the UTUC. This case highlights the importance of tissue confirmation of newly developed lesions and timely etiologic evaluation of abnormal MMR findings in patients with suspected LS. It adds to emerging evidence that PD-1 blockade may have a kidney-preserving role in carefully selected patients with dMMR LS-associated UTUC, although longer radiographic, endoscopic, cytologic, and histologic surveillance is required.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1909587","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:50Z","timestamp":1789706090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney-sparing immunotherapy for lynch syndrome-associated upper tract urothelial carcinoma following colon cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Haibiao","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Second Traditional Chinese Medicine Hospital (Guangdong Research Institute of Traditional Chinese Medicine Engineering and Technology)","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqianyu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]},{"name":"Department of Urology, School of Medicine, South China University of Technology","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]},{"name":"Department of Urology, School of Medicine, South China University of Technology","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02059-z","article-title":"Lynch syndrome, molecular mechanisms and variant classification","volume":"128","author":"Abildgaard","year":"2023","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-016-9882-8","article-title":"Update on lynch syndrome genomics","volume":"15","author":"Peltom\u00e4ki","year":"2016","journal-title":"Fam Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030467","article-title":"Diagnosis of lynch syndrome and strategies to distinguish lynch-related tumors from sporadic MSI\/dMMR tumors","volume":"13","author":"Leclerc","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.058","article-title":"Lynch syndrome genetics and clinical implications","volume":"164","author":"Peltom\u00e4ki","year":"2023","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020531","article-title":"Lynch syndrome: its impact on urothelial carcinoma","volume":"22","author":"Lindner","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2026.110999","article-title":"Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"44","author":"Moryousef","year":"2026","journal-title":"Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000335","article-title":"Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis","volume":"3","author":"Chandran","year":"2024","journal-title":"BMJ Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105969","article-title":"Detection of urothelial carcinoma in lynch syndrome using microsatellite instability analysis of urine cell-free DNA","volume":"121","author":"Hall","year":"2025","journal-title":"EBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00772","article-title":"Efficacy of immune checkpoint blockade in advanced upper tract urothelial cancer with DNA mismatch repair deficiency or microsatellite instability","volume":"10","author":"Moussa","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.1322","article-title":"Hereditary colorectal cancer syndromes: american society of clinical oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: european society for medical oncology clinical practice guidelines","volume":"33","author":"Stoffel","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04156-3","article-title":"Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RaNeO) research consortium)","volume":"40","author":"Tafuri","year":"2022","journal-title":"World J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Sci (N Y NY)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2210","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag050","article-title":"Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial","volume":"31","author":"Wei","year":"2026","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985177","article-title":"Case report: neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis","volume":"12","author":"Chan","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:59Z","timestamp":1789706099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1909587"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1909587","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1909587"}}